

Case Study:

Pharmaceutical company focused on treating infected diabetic foot ulcers

nRollmed increases the monthly recruitment rate



The Challenge:

A pharmaceutical company launched a Phase I/II a study on a novel drug for treating infected diabetic foot ulcers (DFU). After one year of recruitment, 12 subjects were enrolled -26 subjects were needed. The deadline for recruitment was quickly approaching.

The study faced several recruitment challenges:

- The active site was a hospital and during the COVID pandemic, potential subjects were justifiably fearful of hospitals.
- Patients being treated for DFU at the hospital often had ulcers that were too advanced to meet study requirements.
- The ulcer needed to be infected with specific types of bacteria.

nRollmed was brought on to expedite recruitment of the final patients.

nRollmed's Contribution to the Recruitment Process



2 months 260 interested leads



70 leads found eligible and referred to sites 6 patients signed consent



4 patients enrolled 33% screen fail rate The monthly recruitment rate tripled



Customized and Collaborative Approach

nRollmed designed an awareness campaign using print and digital advertising. Leads were pre-screened to ensure only highly qualified patients were referred to the sites.

Once at the site, several additional barriers to participation became apparent.

- Compensation for patients' travel was not well organized, especial for patients traveling long distances. nRollmed found a cab service that established a contract with the sites so that patients didn't have to pay out of pocket.
- nRollmed implemented weekly phone calls to study coordinators and helping schedule patients' visits, to improve site efficiency.
- The doctors' unpredictable schedules made scheduling appointments difficult. To reduce the need for on-site assessment, nRollmed asked patients to send a picture of their ulcer to the study team. Elderly patients were assisted with this process by the nRollmed team.



nRollmed's Method





Results

nRollmed worked within the sponsor's budget and provided 260 leads, exceeding the predicted number by 110. After pre-screening, 70 patients were referred to the sites, of which 6 signed consent. 4 of these were randomized, with a 33% screen fail rate, improving on the sponsor's expected screen fail rate of 60-75%.

In the time that nRollmed was active, seven patients were randomized. nRollmed's referrals made up more than 50% of the enrollments in that time period.

The study, which had been recruiting on average one patient a month for the previous year, increased to enrolling three patients a month. This was due to nRollmed persistence in increasing site attention and commitment to the study, and by nRollmed's work to widen the patient pool.

@ gil.pal@nrollmed.com 🔲 (+972) 54-6204666 +1(646)374-1231 🛛 🌐 www.nRollmed.com